Drug regimen review · Pharmacy Service Deficiencies
Ensure a licensed pharmacist perform a monthly drug regimen review, including the medical chart, following irregularity reporting guidelines in developed policies and procedures.
F756 in New York. Pick another state for the same tag.
Against expectation — 2025
New York cites F756 more often than its own record predicts
Versus expected share1.16×
1.16 times the share F756 takes of citations nationally.
Share of New York citations0.92%
Of every deficiency written in New York in 2025, this is the portion that was F756.
New York0.92%
National0.79%
Share of all citations that were F756.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What New York surveyors wrote
F756 findings written in New York, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
G · Actual harm, isolatedOctober 5, 2021
Based on record review and interview conducted during a Complaint Investigation (Complaint #NY 965) completed during an Abbreviated survey on 10/5/21, the facility failed to ensure that the drug regimen of each resident was reviewed at least once a month by a licensed pharmacist and that the pharmacist reported irregularities to the attending physician and the facility's medical director and director of nursing, and these reports must be acted upon. for one (Resident #1) of three residents reviewed. …
D · No harm, potential for more than minimal, isolatedJune 29, 2026
Based on interview and record review, the facility failed to ensure that irregularities reported in drug regimen reviews were acted upon. This was evident for one (Resident #19) of five residents reviewed for Unnecessary Medications out of a total of 39 sampled residents. Specifically, the physician failed to document the clinical rationale for which a gradual dose reduction was not initiated. The findings include: The facility's policy, Gradual Dose Reduction of Psychotropic Medications, last revised 01/2026, documented that a gradual dose reduction shall be based on the resident's diagnosis, target symptoms, response to treatment, behavioral monitoring, past medical history and overall clinical condition. …
C · No harm, potential for minimal, widespreadMay 26, 2022
Based on record review and interview during the recertification survey, the facility did not ensure a policy was developed, maintained, and implemented for the monthly medication regimen review (MRR) process that included time frames for the different steps in the process and the steps the pharmacist must take when an irregularity that requires urgent action to protect the resident was identified. Specifically, the MRR policy did not document time frames for the steps in the process. Additionally, the MRR policy did not document the steps the pharmacist must take when an identified irregularity requires immediate action to protect the resident and prevent the occurrence of an adverse drug event. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction